| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-08 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.16 | 1e-05 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.18 | 0.0003 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0008 |
| mRNA | Epothilone B | FIMM | pan-cancer | AAC | -0.58 | 0.0008 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0008 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |